{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT02538198","nct_id":"NCT02538198","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02538198. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.","label":"Lenalidomide","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-08","type":"ESTIMATED"},"conditions":["Plasma Cell Myeloma"],"enrollment":{"count":108,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Lenalidomide","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"Lenalidomide Maintenance in Plasma Cell Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"progression-free survival","timeFrame":"5 years"}],"references":[{"citation":"Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, Hultcrantz M, Hassoun H, Lu SX, Tan C, Rustad EH, Maura F, Maclachlan K, Peterson T, Derkach A, Devlin S, Landau HJ, Scordo M, Chung DJ, Shah GL, Lahoud O, Thoren K, Murata K, Ramanathan L, Arcila ME, Ho C, Roshal M, Dogan A, Giralt SA, Landgren O. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021 Jun;8(6):e422-e432. doi: 10.1016/S2352-3026(21)00130-7.","pmid":"34048681","type":"DERIVED"}],"start_date":{"date":"2015-08-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Lenalidomide Maintenance in Plasma Cell Myeloma","url":"https://clinicaltrials.gov/study/NCT02538198"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02538198"}